Literature DB >> 21306896

Investigation of a novel molecular descriptor for the lead optimization of 4-aminoquinazolines as vascular endothelial growth factor receptor-2 inhibitors: application for quantitative structure-activity relationship analysis in lead optimization.

Joel K Kawakami1, Yannica Martinez, Brandi Sasaki, Melissa Harris, Wendy E Kurata, Alan F Lau.   

Abstract

We investigated the use of infrared vibrational frequency of ligands as a potential novel molecular descriptor in three different molecular target and chemical series. The vibrational energy of a ligand was approximated from the sum of infrared (IR) absorptions of each functional group within a molecule and normalized by its molecular weight (MDIR). Calculations were performed on a set of 4-aminoquinazolines with similar docking scores for the VEGFR2/KDR receptor. 4-Aminoquinazolines with MDIR values ranging 192-196 provided compounds with KDR inhibitory activity. The correlation of KDR inhibitory activity was similarly observed in a separate chemical series, the pyrazolo[1,5-a]pyrimidines. Initial exploration of this molecular descriptor supports a tool for rapid lead optimization in the 4-aminoquinazoline chemical series and a potential method for scaffold hopping in pursuit of new inhibitors.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21306896      PMCID: PMC3774784          DOI: 10.1016/j.bmcl.2011.01.037

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  11 in total

Review 1.  The EVA spectral descriptor.

Authors:  D B Turner; P Willett
Journal:  Eur J Med Chem       Date:  2000-04       Impact factor: 6.514

2.  Synthesis and initial SAR studies of 3,6-disubstituted pyrazolo[1,5-a]pyrimidines: a new class of KDR kinase inhibitors.

Authors:  Mark E Fraley; William F Hoffman; Robert S Rubino; Randall W Hungate; Andrew J Tebben; Ruth Z Rutledge; Rosemary C McFall; William R Huckle; Richard L Kendall; Kathleen E Coll; Kenneth A Thomas
Journal:  Bioorg Med Chem Lett       Date:  2002-10-07       Impact factor: 2.823

3.  Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.

Authors:  L F Hennequin; A P Thomas; C Johnstone; E S Stokes; P A Plé; J J Lohmann; D J Ogilvie; M Dukes; S R Wedge; J O Curwen; J Kendrew; C Lambert-van der Brempt
Journal:  J Med Chem       Date:  1999-12-30       Impact factor: 7.446

4.  A validation study of molecular descriptors for the rational design of peptide libraries.

Authors:  H Matter
Journal:  J Pept Res       Date:  1998-10

5.  ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity.

Authors:  C E Whittles; T M Pocock; S R Wedge; J Kendrew; L F Hennequin; S J Harper; D O Bates
Journal:  Microcirculation       Date:  2002-12       Impact factor: 2.628

6.  The role of halogen substitution in classical cannabinoids: a CB1 pharmacophore model.

Authors:  Spyros P Nikas; Jolanta Grzybowska; Demetris P Papahatjis; Avgui Charalambous; Ali R Banijamali; Ravi Chari; Pusheng Fan; Therapia Kourouli; Sonyuan Lin; Albert J Nitowski; Gilbert Marciniak; Yan Guo; Xiuyan Li; Chia-Lin J Wang; Alexandros Makriyannis
Journal:  AAPS J       Date:  2004-10-19       Impact factor: 4.009

7.  Novel potent orally active selective VEGFR-2 tyrosine kinase inhibitors: synthesis, structure-activity relationships, and antitumor activities of N-phenyl-N'-{4-(4-quinolyloxy)phenyl}ureas.

Authors:  Kazuo Kubo; Toshiyuki Shimizu; Shin-ichi Ohyama; Hideko Murooka; Akemi Iwai; Kazuhide Nakamura; Kazumasa Hasegawa; Yoshiko Kobayashi; Noriko Takahashi; Kazumi Takahashi; Shinichiro Kato; Toshio Izawa; Toshiyuki Isoe
Journal:  J Med Chem       Date:  2005-03-10       Impact factor: 7.446

8.  Novel, highly potent adenosine deaminase inhibitors containing the pyrazolo[3,4-d]pyrimidine ring system. Synthesis, structure-activity relationships, and molecular modeling studies.

Authors:  Federico Da Settimo; Giampaolo Primofiore; Concettina La Motta; Sabrina Taliani; Francesca Simorini; Anna Maria Marini; Laura Mugnaini; Antonio Lavecchia; Ettore Novellino; Daniela Tuscano; Claudia Martini
Journal:  J Med Chem       Date:  2005-08-11       Impact factor: 7.446

9.  Discovery of a new class of anilinoquinazoline inhibitors with high affinity and specificity for the tyrosine kinase domain of c-Src.

Authors:  Patrick A Plé; Tim P Green; Laurent F Hennequin; Jon Curwen; Michael Fennell; Jack Allen; Christine Lambert-Van Der Brempt; Gerard Costello
Journal:  J Med Chem       Date:  2004-02-12       Impact factor: 7.446

10.  Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit.

Authors:  Essa Hu; Andrew Tasker; Ryan D White; Roxanne K Kunz; Jason Human; Ning Chen; Roland Bürli; Randall Hungate; Perry Novak; Andrea Itano; Xuxia Zhang; Violeta Yu; Yen Nguyen; Yanyan Tudor; Matthew Plant; Shaun Flynn; Yang Xu; Kristin L Meagher; Douglas A Whittington; Gordon Y Ng
Journal:  J Med Chem       Date:  2008-05-01       Impact factor: 7.446

View more
  2 in total

1.  Exploration for novel inhibitors showing back-to-front approach against VEGFR-2 kinase domain (4AG8) employing molecular docking mechanism and molecular dynamics simulations.

Authors:  Shailima Rampogu; Ayoung Baek; Amir Zeb; Keun Woo Lee
Journal:  BMC Cancer       Date:  2018-03-07       Impact factor: 4.430

2.  Discovery of VEGFR2 inhibitors by integrating naïve Bayesian classification, molecular docking and drug screening approaches.

Authors:  Xiaocong Pang; Wenwen Lian; Lvjie Xu; Jinhua Wang; Hao Jia; Baoyue Zhang; Ai-Lin Liu; Guan-Hua Du
Journal:  RSC Adv       Date:  2018-01-30       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.